Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neonatal Perinatal Med ; 13(2): 267-273, 2020.
Article in English | MEDLINE | ID: mdl-31707376

ABSTRACT

Sustained fetal supraventricular tachycardia (SVT) complicated by hydrops fetalis carries a significant risk of morbidity and mortality. While there is no clear consensus on first- and second-line therapy options for the management of fetal SVT with or without hydrops fetalis, there exists significant nonrandomized experience with a number of antiarrhythmic agents that has founded the basis for management. Furthermore, recently published meta-analyses and ongoing multicenter prospective studies have aimed to bridge the gap in the literature. We report two cases of sustained fetal SVT with severe secondary hydrops fetalis managed successfully with flecainide-sotalol combination therapy in one case and sotalol-digoxin combination therapy in the second and review the literature for the management of fetal SVT.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Digoxin/therapeutic use , Fetal Diseases/drug therapy , Flecainide/therapeutic use , Hydrops Fetalis/drug therapy , Sotalol/therapeutic use , Tachycardia, Supraventricular/drug therapy , Adult , Drug Therapy, Combination , Female , Fetal Diseases/diagnosis , Humans , Hydrops Fetalis/diagnostic imaging , Hydrops Fetalis/etiology , Pregnancy , Tachycardia, Supraventricular/complications , Tachycardia, Supraventricular/diagnosis , Young Adult
2.
Pediatr Cardiol ; 40(3): 610-615, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30607441

ABSTRACT

Atrial septal defect (ASD) is one of the most common congenital heart defects. Transcatheter device closure of ASDs is safe and effective with most of the reported data being described from developed countries. To evaluate the short and mid-term results and experience of device closure of ASDs at a tertiary center in a developing country and compare it to that from developed countries. Retrospective study based on data collection from all patients who have undergone transcatheter percutaneous device closure for ASD from January 2005 until December 2017 at the Children's Heart Center at the American University of Beirut, Medical Center, Lebanon. During the study period, a total of 254 cardiac catheterizations were performed for device closure of ASDs. The mean age of the patients was 18 ± 17.9 years with 37% being less than 6 years of age. Females were 54%. Defect size ranged from 7 to 37 mm and device size ranged from 8 to 40 mm. The procedure was executed with a success rate of 96%. Five patients had device embolization (2%); in one patient the device was snared and for the remainder the devices were removed surgically. None of the study patients had thrombus formation, neurological complications, bacterial endocarditis, or cardiac erosions. There was no mortality. Device closure of ASDs at our tertiary center in a developing country has an effective and safe profile with excellent results and low complications rates, which compare favorably to those reported from centers in developed countries.


Subject(s)
Cardiac Catheterization/methods , Heart Septal Defects, Atrial/surgery , Septal Occluder Device/statistics & numerical data , Adolescent , Adult , Aged , Cardiac Catheterization/adverse effects , Child , Child, Preschool , Developed Countries/statistics & numerical data , Developing Countries/statistics & numerical data , Female , Humans , Infant , Lebanon , Male , Middle Aged , Postoperative Complications/epidemiology , Retrospective Studies , Septal Occluder Device/adverse effects , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...